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Abstract
Summary This case report describes a 38-year-old woman,
who presented with bilateral femoral stress fractures and oste-
oporosis after years of excessive levothyroxine treatment. Her
bone health was restored rapidly and long-lasting with the
reduction of levothyroxine dosage. No bone-active treatment
was warranted.
Introduction Hyperthyroidism is a known risk factor for oste-
oporosis and fractures. Recent studies on patients with serum
thyrotropin-suppressive therapy have not, however, indicated
adverse effects on bone during long-term follow-up.
Methods This case report describes long-term follow-up data
of a clinically euthyreoid patient, who developed symptomatic
osteoporosis due to excessive levothyroxine treatment.
Results After correction of levothyroxine dosage, her bone
mineral density (BMD) and previously elevated serum
osteocalcin levels normalized rapidly and she remained free
from fractures during 23 years of follow-up over menopause.
Conclusion Excessive TSH suppression contributed to the sec-
ondary osteoporosis in this patient; BMD normalized after dose
reduction of levothyroxine and no fractures occurred during 23
years’ follow-up. Some patients develop severe osteoporosis if
they are over-substituted with levothyroxine, and decent
follow-up of patients with levothyroxine supplementation is
mandatory.
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Introduction
Hyperthyroidism is a known cause of accelerated bone turnover
and bone loss and increases the risk of osteoporosis and fragility
fractures. Also, subclinical hyperthyroidism, and even serum
thyrotropin (S-TSH) levels within the low-normal range in eu-
thyroid elderly women, has been shown to increase the risk of
low bone mineral density (BMD) and fractures [1–3]. When
examining patients with long-term levothyroxine treatment,
both high and low S-TSH levels have been indicated to increase
the risk of fragility fractures [4]. Study results are, however,
conflicting. In recent studies neither young nor elderly women
receiving TSH-suppressive therapy after treatment for thyroid
cancer exhibited adverse effects on BMD or fracture rates dur-
ing at least 10 years of follow-up [5, 6].
In this case report, we present the severe consequence of
excessive levothyroxine therapy in an otherwise healthy wom-
an and the complete remission with correction of dosage. The
presentation includes long-term follow-up extending over
menopause.
Case report
A 38-year-old non-smoking woman was referred to the endo-
crine out-patient clinic in 1993 for assessment due to stress
fractures. She had undergone thyroidectomy at the age of
12 years due to a papillary thyroid adenoma and had thereafter
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received levothyroxine replacement therapy. Her postopera-
tive serum calcium levels had been normal. The follow-up in
the primary health care had been insufficient, however, and
she had used a daily dose of 0.3 mg (300 μg) levothyroxine
since her teens. An extensive biochemical assessment includ-
ing screening for other hormone disturbances and chronical
illnesses was normal.
She trained excessively, running 10–20 km 5–6 times a
week, and had recently experienced debilitating pain in both
thighs caused by bilateral femoral stress fractures, which was
confirmed by bone scintigraphy in October 1992. She also had
a recent history of one low-impact forearm fracture and eight
rib fractures at separate occasions, e.g., from lifting a heavy
object. Her anterior-posterior lumbar BMD Z-score (L1-L4)
was −2.5, and the lowest Z-score was −3.2 in L2, and similarly
at the lateral spine projection. Her hip BMD Z-score was
normal; +0.7 (Fig. 1a, b left panel). At the time of the first
bone scintigraphy in 1992, she had a transiently elevated se-
rum calcium level (2.68 mmol/L; reference range 2.15–2.50)
but normal serum alkaline phosphatase (3.1 μkat/L; reference
range 0–5.0). At first assessment at our clinic, she was clini-
cally euthyroid with a heart rate of 78 beats/min and normal
blood pressure. She was of normal build, her menstrual cycle
was regular, and she had two healthy children. She experi-
enced no tremor, excessive perspiration, or palpitations.
Biochemical analyses revealed a high serum free T4 (37 ng/
L; reference range 10–22 ng/L), an undetectable TSH, an el-
evated osteocalcin level, but normal levels of other bone
markers and 25-hydroxyvitamin D. Biochemical markers at
first assessment in February 1993 and during follow-up are
presented in Table 1.
The levothyroxine dose was successively lowered to
0.1 mg (100 μg) daily, and 6 months later, her femoral pain
had subsided, her resting heart rate had dropped to 60 beats/
min, and her weight was unaltered. A bone scintigraphy in
1993 showed diminished isotope uptake in affected femoral
regions, and she was at the time still running 5–10 km 3–4
times a week. She experienced that her physical condition had
improved substantially with the lowering of the resting heart
rate and of the maximum pulse rate during exercise. She soon
thereafter increased her training to previous levels and contin-
ued competing in long-distance running for several years. Her
lumbar spine BMD normalized within 2 years without any
bone-specific treatments or supplements (Fig. 1a, b right
panel). During follow-up for over 20 years, her BMD
remained normal past menopause, and she has not experi-
enced fractures or bone pain despite continuing her active
running regime. The last 10 years, she has mainly participated
in public running happenings and no longer at elite level.
Conclusions
Our patient suffered severe symptoms from her osteoporosis
and her condition was rapidly reversed with a lowering of
levothyroxine dosage. During the most painful phase, before
Fig. 1 Bone mineral density
(BMD) changes pictured over
time in a woman with years of
excessive levothyroxine dosage.
The dosage was reduced at age
38, and she experienced
menopause at age 55. a. Z-scores
during 20 years of follow-up. b.
Left panel: lumbar spine BMD at
age 38 years. Right panel: lumbar
spine BMD at age 40 years
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the stress fractures started healing, she trained by cycling, but
resumed running only 2 months later. Long-distance runners
are known to have lower spine BMD, and her temporary rest
may have contributed to the fast improvement of spine BMD
[7]. On the other hand, she resumed her excessive training
soon thereafter and no decrease in spine BMD could be de-
tected. Her bone health has since remained normal during
20 years and past menopause. At the time of diagnosis, our
patient had an elevated level of serum osteocalcin and normal
serum alkaline phosphatase. In 1993, no other bone turnover
markers could be analyzed at our hospital. Osteocalcin levels
are known to rise with increasing triiodothyronine levels, and
bone resorption markers to decline with treatment for
hyperthyreosis [8, 9]. The association between a hyperactive
thyroid, high-turnover bone loss, and increased risk for frac-
tures is well-established, and reversal of osteoporosis after
thyreostatic treatment has been documented previously
[10–12]. The molecular and cellular mechanism behind
hyperthyreosis-induced osteoporosis is not completely under-
stood. Due to the physiological reciprocal correlation between
thyroid hormones and TSH, it is difficult to clinically discrim-
inate which hormone alteration is the cause of bone loss.
Some results indicate that TSH induces a direct effect on bone
cells through TSH receptors, and low TSH receptor activation
may enhance osteoclast function and downregulate osteoblast
differentiation inducing a state of high-turnover bone metab-
olism, while other studies show that T3 controls bone cells
through activating thyroid hormone receptor α1 [13–15].
While clarification of the molecular and cellular functions
could aid in the development of future remedies for osteopo-
rosis, the treatment of our and similar patients is quite straight-
forward. The goal is to normalize the hypothalamic-pituitary-
thyroid axis and thereby bone health is restored.
For patient groups in need of TSH-suppressive therapy,
e.g., after thyroid malignancy, the issue of bone health is more
complicated. Based on recent studies, low levels of TSH in-
crease the risk for low BMD and fractures, particularly in
postmenopausal women, but since prospective studies on
fracture risk in young women and men are scarce, the risk of
TSH-suppressive therapy is difficult to assess properly [2, 3,
14, 16]. Our patient suffered significantly from her hyperthy-
roid bone condition, but on the other hand, she had used a
higher levothyroxine dose than normally prescribed in TSH-
suppressive therapy (5.0 vs 2–3 μg/kg/day) [6]. This may
explain why her bone status was more severely affected than
in other premenopausal women in presented studies [5, 6].
Other factors, such as heredity and nutrient intake, can also
affect the tendency for bone loss in an individual. The reason
why only her spinal BMD had decreased may be due to the
fact that trabecular bone is more sensitive to high-turnover
states than the weight-bearing cortical bone, as has been seen
previously in TSH-suppressed patients [16, 17]. Her long-
distance running may also have influenced the severity of
her symptoms. However, as she continued the long-distance
running fairly soon, within 2 months, after the fractures, we
believe that the normalized BMD was due to the reduction of
the levothyroxine dose which the patient complied with.
Hence, only one of the two possible contributing factors to
the secondary osteoporosis was treated and the result was
excellent.
The conclusion is that even though levothyroxine supple-
mentation in the hypothyroid patient may seem like a routine
matter for many physicians, we have the responsibility to
monitor our patients regularly to avoid unnecessary side-ef-
fects. Serum free T4 and TSH should be kept within the ref-
erence range for the usual regimen of levothyroxine replace-
ment in hypothyroidism. The levothyroxine dosage to achieve
TSH suppression after thyroid cancer should be titrated to the
smallest possible dose as to avoid complications. For patients
with thyroid cancer, reference guidelines regarding TSH sup-
pression take into account the severity of the malignancy as
well as treatment response. Patients with low-grade malignan-
cy and a structural and biochemical complete response to
treatment should be substituted to a TSH level of 0.5 to
2.0 mU/L; patients with incomplete biochemical response or
increased risk of relapse to a TSH level of 0.1 to 0.5 mU/L and
Table 1 Patient and biochemical
variables during follow-up. The
reference ranges are marked in
parentheses; the reference ranges
which have changed during
follow-up are marked with an
asterisk
1993 1994 1996 2000 2016
Height, cm 172 172 171 170 169
Body weight, kg 60 59 61 60 62
BMI, kg/m2 20.3 19.9 20.9 20.8 21.7
Levothyroxine, average daily dose (μg) 300 125 100 112.5 107
Free T4, pmol/L (10–22) 37 15 15 12 24
T3, nmol/L (1.3–3.1) 2.6 2.4 1.6
TSH, mU/L (0.2–4.2) 0.0001 0.015 0.03 0.28 0.06
Osteocalcin, μg/L (3.0–7.5)(5.4–59)* 9.6 6.8 7.0 6.0 19*
PTH, ng/L (10–64)(1.6–6.9 pmol/L)* 31.8 41.2 53 3.77*
Calcium, mmol/L (2.15–2.5) 2.39 2.37 2.36 2.34 2.5
Ionized calcium, mmol/L(1.18–1.31) 1.30 1.27 1.21 1.23
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patients with a high risk of relapse to a TSH level below
0.1 mU/L [18]. Bone-active treatment was not given to our
patient and was unwarranted in this case of evident secondary
osteoporosis.
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